Diabetes, Vol 41, Issue 3 385-391, Copyright © 1992 by American Diabetes Association

ARTICLES

Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody

KC Herold, JA Bluestone, AG Montag, A Parihar, A Wiegner, RE Gress and R Hirsch
Department of Medicine, Ben May Institute, University of Chicago, Illinois 60637.

Autoreactive T cells mediate diabetes in animal models of insulin-dependent diabetes mellitus (IDDM) and are believed to cause the disease in humans. Therefore, immunotherapies directed against T cells are of particular interest for the treatment of IDDM. One candidate for such immunotherapy is anti-CD3 monoclonal antibodies (MoAbs), but clinical side effects are common with anti-CD3 treatment due to the ability of these MoAbs to activate T cells in vivo. However, F(ab')2 fragments of anti-CD3 are nonactivating and immunosuppressive. We evaluated the effects of whole anti-CD3 MoAb and F(ab')2 fragments in the setting of experimental autoimmune diabetes. Treatment with whole MoAb or F(ab')2 fragments significantly reduced the hyperglycemia induced with multiple low dosages of streptozocin (MDSDM; 232 +/- 23 mg/dl, P less than 0.01 and 235 +/- 16 mg/dl, P less than 0.01 vs. 325 +/- 25 mg/dl, respectively) in male CD1 mice. Both whole MoAb and F(ab')2 fragments suppressed the development of insulitis (P less than 0.001). Treatment with whole MoAb resulted in marked weight loss (10.4 +/- 1.5% of total body wt), and the mice appeared ill and listless, whereas, mice treated with F(ab')2 fragments gained weight (4.9 +/- 5.5% of total body wt) and appeared healthy. Treatment with whole MoAb caused activation of T cells in vivo as reflected by proliferation of freshly isolated spleen cells to recombinant interleukin-2. Depletion of T cells with whole MoAb was more pronounced than with F(ab')2 fragments, and T-cell receptor (TCR) reexpression on remaining cells occurred with F(ab')2 fragments within 48 h after F(ab')2 treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Rydgren, O. Vaarala, and S. Sandler Simvastatin Protects against Multiple Low-Dose Streptozotocin-Induced Type 1 Diabetes in CD-1 Mice and Recurrence of Disease in Nonobese Diabetic Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 180 - 185. [Abstract] [Full Text] [PDF]

				D. T. Chung, T. Korn, J. Richard, M. Ruzek, A. P. Kohm, S. Miller, S. Nahill, and M. Oukka Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells Int. Immunol., August 13, 2007; (2007) dxm078v1. [Abstract] [Full Text] [PDF]

				H. Ishikawa, H. Ochi, M.-L. Chen, D. Frenkel, R. Maron, and H. L. Weiner Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody Diabetes, August 1, 2007; 56(8): 2103 - 2109. [Abstract] [Full Text] [PDF]

				K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes Diabetes, June 1, 2005; 54(6): 1763 - 1769. [Abstract] [Full Text] [PDF]

				S. S. Smith, T. Patterson, and M. E. Pauza Transgenic Ly-49A Inhibits Antigen-Driven T Cell Activation and Delays Diabetes J. Immunol., April 1, 2005; 174(7): 3897 - 3905. [Abstract] [Full Text] [PDF]

				E. L. Masteller, M. R. Warner, W. Ferlin, V. Judkowski, D. Wilson, N. Glaichenhaus, and J. A. Bluestone Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes J. Immunol., November 15, 2003; 171(10): 5587 - 5595. [Abstract] [Full Text] [PDF]

				S.-E. Lamhamedi-Cherradi, S. Zheng, B. A. Hilliard, L. Xu, J. Sun, S. Alsheadat, H.-C. Liou, and Y. H. Chen Transcriptional Regulation of Type I Diabetes by NF-{kappa}B J. Immunol., November 1, 2003; 171(9): 4886 - 4892. [Abstract] [Full Text] [PDF]

				K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, et al. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1692 - 1698. [Abstract] [Full Text] [PDF]

				M. G. von Herrath, B. Coon, T. Wolfe, and L. Chatenoud Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance J. Immunol., January 15, 2002; 168(2): 933 - 941. [Abstract] [Full Text] [PDF]

				S. Kondo, I. Iwata, K. Anzai, T. Akashi, S. Wakana, K. Ohkubo, H. Katsuta, J. Ono, T. Watanabe, Y. Niho, et al. Suppression of insulitis and diabetes in B cell-deficient mice treated with streptozocin: B cells are essential for the TCR clonotype spreading of islet-infiltrating T cells Int. Immunol., July 1, 2000; 12(7): 1075 - 1083. [Abstract] [Full Text] [PDF]

				R. H. Slover and G. S. Eisenbarth Prevention of Type I Diabetes and Recurrent {beta}-Cell Destruction of Transplanted Islets Endocr. Rev., April 1, 1997; 18(2): 241 - 258. [Abstract] [Full Text]